Recent Advances on Phagocytic B Cells in Teleost Fish

Phagocytosis requires receptor-mediated recognition of particles, usually in the guise of infectious agents and apoptotic cells. Phagosomes fuse with lysosomes to generate phagolysosomes, which play a key role in enzymatic digestion of the internalized contents into component parts. Recent findings indicate that a simple paradigm of a single cognate receptor interaction that guides the phagosome to phagolysosome formation belies the complexity of combinatorial receptor recognition and diversity of phagosome function. In fact, phagosomes are comprised of hundreds of proteins that play a key role in deciphering the contents of the phagosome and in defining host response. In this review we discuss how the challenge of recognizing diverse molecular patterns is met by combinatorial interactions between phagocytic receptors. Furthermore, these combinations are dynamic and both sculpt the balance between a proinflammatory or anti-inflammatory response and direct phagosome diversity. We also indicate an important role for genetically tractable model organisms in defining key components of this evolutionarily conserved process.

What is known about the biological activity of fish cytokines is reviewed. Most of the functional studies performed to date have been in teleost fish, and have focused on the induced effects of cytokine recombinant proteins, or have used loss- and gain-of-function experiments in zebrafish. Such studies begin to tell us about the role of these molecules in the regulation of fish immune responses and whether they are similar or divergent to the well-characterised functions of mammalian cytokines. This knowledge will aid our ability to determine and modulate the pathways leading to protective immunity, to improve fish health in aquaculture.

Receptors that recognize conserved pathogen molecules are the first line of cellular innate immunity defense. Toll-like receptors (TLRs) are the best understood of the innate immune receptors that detect infections in mammals. Key features of the fish TLRs and the factors involved in their signaling cascade have high structural similarity to the mammalian TLR system. However, the fish TLRs also exhibit very distinct features and large diversity which is likely derived from their diverse evolutionary history and the distinct environments that they occupy. Six non-mammalian TLRs were identified in fish. TLR14 shares sequence and structural similarity with TLR1 and 2, and the other five (TLR19, 20, 21, 22 and 23) form a cluster of novel TLRs. TLR4 was lost from the genomes of most fishes, and the TLR4 genes found in zebrafish do not recognize the mammalian agonist LPS and are likely paralogous and not orthologous to mammalian TLR4 genes. TLR6 and 10 are also absent from all fish genomes sequenced to date. Of the at least 16 TLR types identified in fish, direct evidence of ligand specificity has only been shown for TLR2, TLR3, TLR5M, TLR5S and TLR22. The common carp TLR2 was shown to recognize the synthetic triacylated lipopeptide Pam(3)CSK(4) and lipopeptides from gram positive bacteria. The membrane-bound TLR5 (TLR5M) signaling in response to flagellin in rainbow trout is amplified through interaction with the soluble form (TLR5S) in a positive loop feedback. In Fugu, TLR3 is localized to the endoplasmic reticulum (ER) and recognizes relatively short dsRNA, while TLR22 has a surveillance function like the human cell-surface TLR3. Genome and gene duplications have been major contributors to the teleost's rich evolutionary history and genomic diversity. Duplicate or multi-copy TLR genes were identified for TLR3 and 7 in common carp, TLR4b, 5, 8 and 20 in zebrafish, TLR8a in rainbow trout and TLR22 in rainbow trout and Atlantic salmon. The main task for current and near-future fish TLRs research is to develop specificity assays to identify the ligands of all fish TLRs, which will advance comparative immunology research and will contribute to our understanding of disease resistance mechanisms in fish and the development of new adjuvants and/or more effective vaccines and therapeutics. Published by Elsevier Ltd.